|
Market Report
|
Insomnia-Strong brand identity critical to differentiation in an increasingly crowded market
Ambien has remained the clear leader in the insomnia market for over a decade, with 2006 sales of over $2.3 billion across the seven major markets. The success of Ambien is attributable to a favorable side-effect profile and half-life. However, due to recent patent expiries in the US and Japan, Ambien's leadership status is finally under threat and the market is undergoing some dramatic changes.
|
|
Read more...
|
|
|
Market Report
|
Multiple Sclerosis - Continued growth makes the MS market a highly attractive investment
The dynamic MS market continues to grow unabated; seven major market revenues increased 14.7% from 2005 to $4.6 billion in 2006. Growth is driven by the highly successful beta-interferon brands, Teva's Copaxone (glatiramer acetate), and the recent relaunch of Tysabri; the first launch of a new MS treatment for six years.
|
|
Read more...
|
|
|
Market Report
|

Osteoporosis - Risk management and reformulation offer best defense against generic onslaught
The osteoporosis market is due a major upheaval when market leader Fosamax (alendronate) loses its US patent. The resultant heightened competition will force market players to implement radical lifecycle management strategies to safeguard their franchise revenue. New market entrants provide further complexity to the competitive landscape but will also drive market growth over the next ten years.
|
|
Read more...
|
|
|
Market Report
|
Monoclonal Antibodies Report Market Model
The model provides a comprehensive analysis of the mAb market, forecasting its commercial evolution out to 2012 and assessing trends by product, company, therapy area, technology and target type. It also provides an insight into the direction of mAb technology evolution and an analysis of pipeline dynamics.
|
|
Read more...
|
|
|
Market Report
|
Top 20 Cancer Therapy Brands - Sales of targeted therapies overtake cytotoxics in 2006
Sales of the Top 20 cancer therapy brands in each of the seven major markets totaled $24.5 billion in 2006 and are forecast to grow at a CAGR of 6.6% to $45.9 billion by 2016. Four newly marketed drugs are expected to become part of the Top 20 cancer therapy brands during the forecast period and are set to increase the 2016 sales of the existing Top 20 cancer therapy brands to $52.7 billion.
|
|
Read more...
|
|
|
Company Report
|
Disease Management and Drug Adherence: Strategies to support patients and enhance treatment persistence
Failure to take medication as prescribed significantly increases the risk that patients will experience complications resulting in injury or death, and propagate higher healthcare costs overall. The medical establishment's approach to adherence is changing as it becomes clear that the responsibility of achieving adherence is not solely the patient's, but rather is shared among stakeholders.
|
|
Read more...
|
|
|
Market Report
|
Primary Brain Cancer
Incidence of primary brain cancer across the seven major markets in 2007 is estimated to be 47,000. Over half of these cases will be glioblastoma multiforme, for which survival prospects are dismal. The median survival for this group of patients is 1.2 years and only 27% of patients are alive after two years. The level of unmet need is therefore high in this disease.
|
|
Read more...
|
|
|
Market Report
|
Asthma & COPD - Combination products still have blockbuster potential
Detailed analysis of the Asthma and COPD market. 10 year sales forecast for all major drugs brands in these indications, taking into account new treatment trends, clinical trial data, patent expirations and key new product launches in the 7 major markets.
|
|
Read more...
|
|
|
Market Report
|

HIV - Reshaping Treatment Paradigms
Detailed analysis of the antiretroviral therapy market. 10 year sales forecast for marketed drugs and key pipeline compounds, factoring in clinical trial results, new product launches and patent expiries.
|
|
Read more...
|
|
|
Market Report
|
Upper GI Disorders - Generics will limit pipeline profit
Gastroesophageal reflux disease (GERD), functional dyspepsia (FD) and peptic ulcer disease (PUD) represent a group of common gastrointestinal (GI) conditions, which can be referred to collectively as upper GI disorders. Gastric acid suppression remains the cornerstone of therapy in upper GI disorders, with particular focus on reducing symptoms and eradicating H. pylori, if present.
|
|
Read more...
|
|
|
Market Report
|

The competitive cost-conscious antidyslipidemics market presents challenges
The restrictive, highly competitive antidyslipidemic market is going to become even further genericized, which will add to the challenges that drug makers are facing. Despite over 300m people being eligible for antidyslipidemic treatment, there is still a lot of under-diagnosis and under-treatment, but it will be a major issue capturing all the eligible population.
|
|
Read more...
|
|
|
Market Report
|
New class opportunity offset by key patent expiries
Datamonitor expects the antihypertensives market to reach almost $40 billion, across the seven major markets, by 2016. The growth will be driven by the uptake of Novartis's Tekturna, as well as increased use of ARBs, and their combinations. However, the expiries of some key patents, particularly Pfizer's Norvasc and Merck's Cozaar, will restrain market growth.
|
|
Read more...
|
|
|
Market Report
|
Empowered patients can change healthcare outcomes and impact the pharmaceutical industry
Datamonitor has identified the key trends and events that drive patient empowerment and impact the pharmaceutical industry. These range from the increased access to information via internet and the rising pressures of cost containment through to how patient empowerment is affecting access to drugs as well as changing pharmaceutical marketing strategies and their public image.
|
|
Read more...
|
|
|
Market Report
|
Pediatric and Adolescent Vaccines
The pediatric and adolescent vaccines market encompasses many different classes. DTP and MMR combinations continue to form the mainstay of childhood immunization; however, their growth potential is limited. The key opportunities lie in novel, innovative additions to established schedules, particularly pneumococcal (Prevnar), conjugated meningococcal (Menactra) and HPV (Gardasil) vaccines.
|
|
Read more...
|
|
|
Market Report
|
Female Sexual Dysfunction: Prescription Drug Pipeline Overview 2007
Female sexual dysfunction (FSD) affects an estimate 84 million women across the seven major pharmaceutical markets and represents a significant opportunity for investment. Despite its high prevalence, FSD is poorly understood and defined. Currently there is just one product approved for the treatment of FSD; P&G's Intrinsa (testosterone) is marketed in Germany, France and the UK.
|
|
Read more...
|
|
|
Market Report
|
Health Care Equipment and Supplies: Global Industry Guide
Datamonitor's Health Care Equipment & Supplies: Global Industry Guideis an essential resource for top-level data and analysis covering the health care equipment & supplies industry. It includes detailed data on market size and segmentation, textual analysis of the key trends and competitive landscape, and profiles of the leading companies. This incisive report provides expert analysis on a global, regional and country basis.
|
|
Read more...
|
|
|
Company Report
|

Incremental improvements and paradigm shifts in strategy are both necessary to boost productivity
Waves of technological advancements have powered significant evolution in R&D from serendipitous drug discovery, through to rational drug design. However, as the low-hanging fruit has been picked, and recent technological advances have failed to yield high numbers of new therapies, the search is on to identify R&D strategies to improve R&D productivity.
|
|
Read more...
|
|
|
Market Report
|
Heart failure - Weak pipeline dominated by new indications and add-on diuretics
Datamonitor expects few new products to emerge from a week pipeline for both acute and chronic heart failure. Sales in the seven major markets will be modest with all the new drugs being add-on therapies to current standard regimes. Significant unmet patients needs will remain in both acute and chronic heart failure.
|
|
Read more...
|
|